Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 4/20 | 0.71 |
| ▸ | HTR2B | P41595 | 3/20 | 0.67 |
| ▸ | HTR2C | P28335 | 2/20 | 0.67 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.66 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.64 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.64 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | DRD1 | P21728 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6586520 | 0.88 | IGF1R (0.79) | IGF1RS1PR1OPRD1MAPTMEN1 | |
| SCHEMBL6591375 | 0.88 | S1PR1 (0.63) | IGF1RHTR2BHTR2CS1PR1OPRD1 | |
| SCHEMBL6588598 | 0.87 | IGF1R (0.77) | IGF1RS1PR1OPRD1MAPTMEN1 | |
| SCHEMBL5802430 | 0.87 | IGF1R (0.76) | IGF1RHTR2BHTR2CS1PR1OPRD1 | |
| SCHEMBL4855474 | 0.85 | HTT (0.75) | IGF1RS1PR1OPRD1MAPTMEN1 | |
| SCHEMBL4902799 | 0.85 | IGF1R (0.64) | IGF1RHTR2BHTR2CS1PR1OPRD1 | |
| SCHEMBL6588862 | 0.85 | IGF1R (0.77) | IGF1RS1PR1OPRD1MAPTMEN1 | |
| SCHEMBL7694541 | 0.83 | IGF1R (0.71) | IGF1RS1PR1OPRD1MAPTMEN1 | |
| SCHEMBL6586190 | 0.83 | IGF1R (1.00) | IGF1RS1PR1OPRD1MAPTMEN1 | |
| SCHEMBL6587428 | 0.82 | IGF1R (0.70) | IGF1RS1PR1OPRD1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699879-B1 | OBESITY, DIABETES, SLEEP DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-02 | — | — | US | claimed |
| US-20060178307-A1 | Modulation of NMDA receptor currents via orexin receptor and/or CRF receptor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-08-10 | — | — | US | disclosed |
| WO-2006081522-A2 | MODULATION OF NMDA RECEPTOR CURRENTS VIA OREXIN RECEPTOR AND/OR CRF RECEPTOR | THE REGENTS OF THE UNVERSITY OF CALIFORNIA (US) | 2006-08-03 | — | — | WO | disclosed |
| EP-1150977-B1 | PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-08-25 | — | — | EP | disclosed |
| US-6699879-B1 | OBESITY, DIABETES, SLEEP DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-02 | — | — | US | disclosed |
| EP-1150977-A1 | PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000047577-A1 | PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178307-A1 | Modulation of NMDA receptor currents via orexin receptor and/or CRF receptor | HCRTR2, HCRTR1, GRIN2B | IGF1R 1428/4885HTR2B 84/4885HTR2C 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.